BackgroundCheck.run
Search For

John P Mcmichael, 692465 Dogwood Dr, Wexford, PA 15090

Known as:
John Carolyn Mcmichael Carolyn Louise Mcmichael Carolyn L Mcmichael John Patrick Mcmicha Carolyn Mc Michael John P Mcmicha John Mc Michael

John Mcmichael Phones & Addresses

2465 Dogwood Dr, Wexford, PA 15090    724-9344369    724-9337874   

Brunswick, OH   

Pittsburgh, PA   

Manchester, IA   

Bear, DE   

Medina, OH   

Lovettsville, VA   

2465 Dogwood Dr, Wexford, PA 15090    724-6837853   

Work

Position: Professional/Technical

Education

Degree: High school graduate or higher
Get Report
Control this profile

Mentions for John P Mcmichael

John Mcmichael resumes & CV records

Resumes

John Mcmichael Photo 39

Quality Manager At Prestolite Performance Llc

Location:
Cleveland/Akron, Ohio Area
Industry:
Electrical/Electronic Manufacturing
John Mcmichael Photo 40

Quality Manager

Location:
588 south Eliseo Dr, Greenbrae, CA 94904
Industry:
Electrical/Electronic Manufacturing
Work:
Prestolite Performance LLC since Sep 2009
Quality Manager Universal Electronics Jun 2009 - Aug 2009
Quality Management Consultant Ranpak Jan 2003 - Oct 2008
Director of Quality Halex Company Oct 1998 - Dec 2002
Quality Manager Universal Electronics May 1995 - Apr 1998
Director of Quality IBM Mar 1994 - May 1995
Procurement Manufacturing Engineer IBM Jun 1984 - Feb 1994
Quality Assurance Engineer
Education:
Rensselaer Polytechnic Institute 1990
Purdue University 1980 - 1984
Skills:
Manufacturing, Quality System, Six Sigma, Quality Management, Cross Functional Team Leadership, Continuous Improvement, Lean Manufacturing, Product Development, Quality Assurance, Fmea, Process Improvement, Iso, Iso 9000, Quality Control, Management, Root Cause Analysis, Ppap, Value Stream Mapping, Spc, Automotive, Strategic Planning, Manufacturing Operations Management, Operations Management, Kaizen, Leadership, Dmaic, Manufacturing Engineering, Team Building, 5S, Engineering Management, Supply Chain, Supply Chain Management, Project Management, Business Process Improvement, Machining, Process Engineering, Supplier Quality, Components, Forecasting, Engineering, Product Management, Procurement, Inventory Management, Design of Experiments, Tqm, Production Planning, Purchasing, Operational Excellence, Mrp, Pricing
John Mcmichael Photo 41

Associate Chief Medical Information Officer, General Surgery

Location:
Pittsburgh, PA
Industry:
Medical Devices
Work:
Cleveland Clinic Apr 2011 - Aug 2013
It Manager Allogen Lab Cleveland Clinic Apr 2011 - Aug 2013
Associate Chief Medical Information Officer, General Surgery Upmc 2005 - Mar 2011
Systems Analyst Expert Management Science Associates, Inc. 2003 - 2005
Medical Director
Education:
University of Waterloo 1977 - 1981
Skills:
Data Integration, Clinical Trials, Information Security, Surgery, Financial Data, U.s. Health Insurance Portability and Accountability Act, Electronic Medical Record, Infectious Diseases, Clinical Data Management, Physicians, Hipaa, Clinical Research, Prolog, Medical Terminology, Healthcare, Life Sciences, Healthcare Information, Medical Devices, Natural Language Processing, Public Health, Critical Care, Lifesciences, Clinical, Emr, Healthcare It, Oncology, Healthcare Information Technology, Fda Gmp, Nursing, Interface Builder, Cancer, Natural Language, Medical Imaging, Informatics, Quality Improvement, Financial Data Management, Healthcare Management, Patient Safety, Information Assurance, Healthcare Consulting, Hospitals
John Mcmichael Photo 42

John Mcmichael

John Mcmichael Photo 43

John Mcmichael

John Mcmichael Photo 44

John Mcmichael

John Mcmichael Photo 45

John Mcmichael

John Mcmichael Photo 46

John Mcmichael

Location:
United States

Publications & IP owners

Us Patents

Method And Apparatus For Use In Treating A Patient With Any Drug To Optimize Therapy And Prevent An Adverse Drug

US Patent:
6575169, Jun 10, 2003
Filed:
Apr 10, 2001
Appl. No.:
09/832090
Inventors:
John P. McMichael - Wexford PA
Assignee:
The RxFiles Corporation - Nokomis FL
International Classification:
A61B 1900
US Classification:
128898, 600300
Abstract:
A method and system for use in treating a patient receiving any drug to optimize therapy and to prevent an adverse drug response. This system employs surrogate markers or indicators, including blood levels of drug, to determine the next required dose for a patient. Virtually any indicator can be used as the surrogate marker. Surrogate markers could include any measure of the effectiveness of a drugs action. Given the effectiveness of the drugs action, relative to the surrogate markers, a change in drug dose is calculated by the system which uses a stochastic loop mechanism. Conversely, by employing this system, one could determine the expected result of a drug dose change based on the surrogate markers.

Method And Apparatus Using Ids™ For Multi-Agent Therapy

US Patent:
6578582, Jun 17, 2003
Filed:
Aug 24, 2001
Appl. No.:
09/939056
Inventors:
John P. McMichael - Wexford PA
Assignee:
The RxFiles Corporation - Nokomis FL
International Classification:
A61B 1900
US Classification:
128898, 600300
Abstract:
A method and apparatus using IDSâ technology to calculate new agent doses in a multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect which each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Method, Apparatus And System For Use In Treating Patient With A Drug Having An Antineoplastic Effect To Optimize Therapy And Prevent An Adverse Drug Response

US Patent:
6581606, Jun 24, 2003
Filed:
Mar 26, 2001
Appl. No.:
09/817906
Inventors:
John D. Kutzko - Nokomis FL
John P. McMichael - Wexford PA
Michaeal G. Singer - Harrisville MI
Assignee:
The Rx Files Corporation - Nokomis FL
International Classification:
A61B 1900
US Classification:
128898, 600300
Abstract:
A method, apparatus and system for use in treating a patient receiving an antineoplastic drug to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the antineoplastic drug to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the antineoplastic drugs action. Given the effectiveness of the antineoplastic drugs action relative to the surrogate markers, a change in antineoplastic drug dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the antineoplastic drug dose change on the surrogate markers.

Method And System For Use In Treating A Patient With A Biological Substance To Optimize Therapy And Prevent An Adverse Response

US Patent:
6581607, Jun 24, 2003
Filed:
Jul 27, 2001
Appl. No.:
09/916411
Inventors:
John D. Kutzko - Nokomis FL
John P. McMichael - Wexford PA
Michaeal G. Singer - Harrisville MI
Assignee:
The Rx Files Corporation - Nokomis FL
International Classification:
A61B 1900
US Classification:
128898, 600300
Abstract:
A method, system and apparatus for use in treating a patient receiving a biological substance, such as a cancer vaccine, to optimize therapy and prevent an adverse response. This system employs surrogate markers or indicators including blood levels of the vaccine to determine the next required dose for a patient. Since the surrogate markers may be employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the vaccines action. Given the effectiveness of the vaccines action relative to the surrogate markers, a change in vaccine dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the vaccine dose change on the surrogate markers.

Method And Apparatus For Dosing Single And Multi-Agent Therapy

US Patent:
6883521, Apr 26, 2005
Filed:
Jun 3, 2003
Appl. No.:
10/453749
Inventors:
John P. McMichael - Wexford PA, US
Assignee:
Dimensional Dosing Systems, Inc. - Nokomis FL
International Classification:
A61B019/00
US Classification:
128898, 600300
Abstract:
An improved method and apparatus using a newly defined nonlinear technology that more accurately describes the biological process of dose titration to calculate next agent dose(s) in single and multi-agent therapy. The overall proportion of each agent is determined by the amount of agent as it relates to the dosing range. The overall proportion as well as the intrinsic potency of the agent is used to determine the total proportional effect that each agent has on the surrogate marker. This parameter is then inserted into the four-parameter equation for calculating dose by adjusting the proportional change in marker that is attributed to the activity of the agent.

Method And System For Use In Treating A Patient With An Anticoagulant To Optimize Therapy And Prevent An Adverse Drug Response

US Patent:
6942614, Sep 13, 2005
Filed:
Aug 24, 2000
Appl. No.:
09/644503
Inventors:
John D. Kutzko - Nokomis FL, US
Michaeal G. Singer - Harrisville MI, US
John McMichael - Wexford PA, US
Assignee:
Dimensional Dosing Systems, Inc. - Wexford PA
International Classification:
A61B005/00
A61B019/00
G06F017/00
US Classification:
600300, 128898, 700 90
Abstract:
A method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and prevent an adverse drug response. This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Since the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.

Gonococcal Pili Processes For The Preparation Thereof And The Use Thereof For The Detection Of And Prevention Of Infections Caused By Neisseria Gonorrhoeae

US Patent:
4461838, Jul 24, 1984
Filed:
Sep 18, 1980
Appl. No.:
6/188463
Inventors:
Charles C. Brinton - Pittsburgh PA
John C. McMichael - Imperial PA
Assignee:
Bactex, Inc. - Pittsburgh PA
International Classification:
G01N 3100
G01N 3348
US Classification:
436511
Abstract:
There are provided a crystalline and single rod products derivable from the Pili of Type 1 and Type 2 Neisseria gonorrhoeae organisms. There are provided methods of growing said organisms to produce the maximum yield of Pili and procedures for purifying said Pili to produce said crystalline material. There are further provided methods of utilizing said Pili to determine the presence, in a system infectable by N. gonorrhoeae organisms, of antibodies to the Pili of said organisms, and methods of serotyping said Pili. There is also provided a mode of utilizing said crystalline material to provide a substantial degree of immunization to infection by N. gonorrhoeae in mammalian systems susceptible to such infection.

Gonococcal Pili Processes For The Preparation Thereof And The Use Thereof For The Detection Of And Prevention Of Infections Caused By Neisseria Gonorrhoeae

US Patent:
4696896, Sep 29, 1987
Filed:
Mar 19, 1984
Appl. No.:
6/590544
Inventors:
Charles C. Brinton - Pittsburgh PA
John C. McMichael - Imperial PA
Assignee:
Bactex, Inc. - Pittsburgh PA
International Classification:
G01N 33531
G01N 33544
G01N 33569
A61K 39095
US Classification:
435 7
Abstract:
There are provided a crystalline and single rod products derivable from the Pili of Type 1 and Type 2 Neisseria gonorrhoese organisms. There are provided methods of growing said organisms to produce the maximum yield of Pili and procedures for purifying said Pili to produce said crystalline material. There are further provided methods of utilizing said Pili to determine the presence, in a system infectable by N. gonorrhoese organisms, of antibodies to the Pili of said organisms, and methods of serotyping said Pili. There is also provided a mode of utilizing said crystalline material to provide a substantial degree of immunization infection by N. gonorrhoese in mammalian systems susceptible to such infection.

Possible Relatives

David L Mcmichael  Davonda Mcmichael  Dale R Mcmichael  Dalton L Mcmichael  Daniel R Mcmichael  Aaron Mcmichael  Denise A Mcmichael  John M Johnson  John Stamps  John R Stan 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.